Syneron Bio closed a $150 million Series B round to support its macrocyclic peptide drug discovery platform. The company said the financing follows a prior round of nearly $100 million and complements earlier momentum generated by an AstraZeneca biobucks deal. The funding reinforces investor confidence in macrocyclic peptide modalities—an area where design constraints and manufacturability have historically slowed translation, but where platform differentiation can accelerate candidate selection for clinical development.